Loading...
•
Mar 31
ACADIA Q1 2025 Earnings Report
Reported First Quarter 2025 Financial Results and Operating Overview
Key Takeaways
Acadia Pharmaceuticals reported a strong start to 2025 with total revenues of $244.3 million in the first quarter, representing a 19% year-over-year increase. Both NUPLAZID and DAYBUE product sales contributed to the growth, with NUPLAZID sales up 23% and DAYBUE sales up 11%. The company also highlighted progress in its pipeline, accelerating the timeline for the COMPASS PWS Phase 3 study results.
Total revenues for the first quarter of 2025 were $244.3 million, a 19% increase year-over-year.
NUPLAZID net product sales reached $159.7 million, growing 23% compared to the first quarter of 2024.
DAYBUE net product sales were $84.6 million, an 11% increase year-over-year, with unique patients shipped increasing by 9.5%.
The company accelerated the timeline for topline results from the COMPASS PWS Phase 3 study of ACP-101 to early in the fourth quarter of 2025.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.comDAYBUE Sales Revenue
CapyFin.com Forward Guidance
Acadia Pharmaceuticals reiterated its full year 2025 financial guidance, with an updated range for R&D expenses.
Positive Outlook
- Reiterates full year 2025 Total Revenues guidance range of $1.03 to $1.095 billion (U.S. only).
- Reiterates full year 2025 NUPLAZID net product sales guidance range of $650 to $690 million.
- Reiterates full year 2025 DAYBUE net product sales guidance range of $380 to $405 million (U.S. only).
- Accelerated timeline for COMPASS PWS Phase 3 study topline results to early Q4 2025.
- Anticipates submitting a New Drug Application for ACP-101 in Q1 2026 if Phase 3 results are positive.
Challenges Ahead
- Increased full year 2025 R&D expense guidance range to $330 to $350 million (up from $310 to $330 million).
- Full year 2025 SG&A expense guidance range of $535 to $565 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income